A new strategic research collaboration between Swiss cancer giant Roche (ROG: SIX) and Chinese biotech Innovent Biologics (HKEX: 01801) has sent shares in the latter climbing 4% in Hong Kong.
Based in Suzhou, Innovent is focused on developing and commercializing therapies in cancer, metabolic, autoimmune and other major diseases.
The firm brought in revenues of over 1 billion renminbi ($141 million) in 2019, driven by its only approved product, Tyvyt (sintilimab injection), a Hodgkin's lymphoma therapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze